This Article  • References  • Full text PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Contact me when this article is cited  Related Content  • Similar articles in JAMA  Social Bookmarking   What's this?

Judd W. Moul, MD
Walter Reed Army Medical Center Bethesda, Md

JAMA. 1997;278(9):699.

	Since this article does not have an abstract, we have provided the first 150 words of the full text PDF and any section headings.

To the Editor.

—I read with great interest the articles by Dr Catalona and colleagues¹ and Dr Carter and colleagues² regarding prostate-specific antigen (PSA) detection for prostate cancer. On one hand, Catalona et al found that the cancer detection rate was 22% when the screening PSA value was between 2.5 and 4.0 ng/mL and implied that vigilance was necessary in these men with lower PSA values. On the other hand, Carter et al found that considering as normal a PSA between 4.0 and 5.0 ng/mL maintains an acceptable ability to diagnose curable cancer and also suggested that men whose initial PSA level is less than 2.0 ng/mL may have screening every other year.

Of great concern is that both studies lacked sufficient numbers of black men, who are known to have a higher prevalence of the disease and a propensity for more advanced cancer at diagnosis.^3,4 With . . . [Full Text PDF of this Article]

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?